Matching articles for "Slynd"

Addendum: Drospirenone (Slynd) - A New Progestin-Only Oral Contraceptive

   
The Medical Letter on Drugs and Therapeutics • March 23, 2020;  (Issue 1594)
In our article on Slynd (Med Lett Drugs Ther 2020; 62:18), the drospirenone-only oral contraceptive, we mentioned that drospirenone has antiandrogenic activity that could improve acne and...
In our article on Slynd (Med Lett Drugs Ther 2020; 62:18), the drospirenone-only oral contraceptive, we mentioned that drospirenone has antiandrogenic activity that could improve acne and antimineralocorticoid activity that could cause hyperkalemia. We should have added that concurrent use of drospirenone with other drugs that increase potassium levels, such as the anti-androgen aldosterone receptor antagonist spironolactone (Aldactone, and generics), which is often used off-label for treatment of acne, can increase the risk of hyperkalemia.
Med Lett Drugs Ther. 2020 Mar 23;62(1594):48 | Show Full IntroductionHide Full Introduction

Drospirenone (Slynd) - A New Progestin-Only Oral Contraceptive

   
The Medical Letter on Drugs and Therapeutics • February 10, 2020;  (Issue 1591)
The FDA has approved a progestin-only oral contraceptive ("minipill") containing drospirenone (Slynd – Exeltis). All other progestin-only oral contraceptives available in the US contain norethindrone...
The FDA has approved a progestin-only oral contraceptive ("minipill") containing drospirenone (Slynd – Exeltis). All other progestin-only oral contraceptives available in the US contain norethindrone (Camila, and others). Progestin-only oral contraceptives are similar in efficacy to combination oral contraceptives. They are used predominantly by breastfeeding women and by those in whom estrogen is poorly tolerated or contraindicated. Combination oral contraceptives containing drospirenone and ethinyl estradiol have been available for years.
Med Lett Drugs Ther. 2020 Feb 10;62(1591):18-9 | Show Full IntroductionHide Full Introduction